In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
about
Three decades of beta-lactamase inhibitorsEmerging threat of multidrug resistant bugs--Acinetobacter calcoaceticus baumannii complex and methicillin resistant Staphylococcus aureus.Multidrug resistant acinetobacter.A focus on intra-abdominal infections.Risk factors and antibiotic resistance of pneumonia caused by multidrug resistant Acinetobacter baumannii in pediatric intensive care unit.High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004.Acinetobacter baumannii: emergence of a successful pathogenA case of IMP-4-, OXA-421-, OXA-96-, and CARB-2-producing Acinetobacter pittii sequence type 119 in Australia.Beta-lactamase inhibitors: evolving compounds for evolving resistance targets.Global challenge of multidrug-resistant Acinetobacter baumanniiSevere pneumonia in the elderly: a multivariate analysis of risk factors.Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections.In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii.Treatment options for multidrug-resistant nonfermenters.Treatment of Acinetobacter infections.Pharmacokinetic evaluation of piperacillin-tazobactam.The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms.Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.A comparison of clinical and microbiological efficacy of antibiotic regimens against Acinetobacter baumannii.Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods.Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.Antimicrobial Susceptibilities of Clinical Acinetobacter baumannii Isolates With Different Genotypes.Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii.Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam.Retrospective evaluation of a possible interaction between warfarin and levofloxacin.Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong.Multidrug-resistant from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam
P2860
Q24646623-9C33DAB5-A513-4C76-B673-15402699C1F5Q30428330-4690BF11-22CB-41C2-80B2-70D8649984F1Q33711902-B955CAB7-FBED-4871-93D3-F027E3C5DC84Q33763449-3E5D5790-1665-4A20-A981-2DEF606105D2Q34032025-4CDD4A16-F5BA-495E-8437-E8606CF69337Q34576870-BB0FF7B7-40D2-4490-BEE2-E39BDA2A2328Q34795807-0D3941E6-E284-410D-848D-9FACE953B0F2Q34983227-954CFE5B-C2AE-4795-A517-9CA73FE55E2DQ35906971-AD64DD61-33D7-4871-A80D-339279A6D1D6Q36095081-AFF74DC9-127F-4845-BEC7-D166DD2FAC7FQ36182731-F2190FC7-6851-49DC-9540-5CA92E33FC89Q36322117-15E71938-AF9F-4DBE-ACC9-24E9473D73DFQ37392820-C2979CF8-E6B8-4C3D-9F47-6422650E4F1CQ37700555-7A068C75-D169-425B-A025-A3E36E11C8ECQ37704397-E3E3F70D-C62E-4B99-8310-19264E604D95Q37773368-550E9E80-E20C-43D0-A46B-F2CCB6EF9B3AQ37954711-8DF46045-161D-4D4E-96BE-B17DBB86E948Q39882067-FE6EF497-4DBC-4097-BBB4-A975835638BAQ40264573-6E38F542-2411-4B79-B5CF-C4895D3EFDE7Q40282151-29CDB98D-2F4B-40EC-A587-36E6AB21D8A8Q40526821-785D9122-8AE0-454D-889E-92F3F030756AQ41445964-E4419F96-B441-45F4-B867-1012094A5A96Q41449165-335BDC82-007E-4B5A-A54E-015B648EBF4DQ41561999-ED676E70-B6D8-4CF5-B6F3-6C1ADDB3567FQ45076608-80D587CA-4583-4060-BF8C-257B70CDB896Q46296415-CDDD6939-1412-40DD-97D4-3DE7C144714CQ46378368-68B307C4-A75A-49A6-B888-742F066F1849Q46653075-5A0DB75F-13B4-4801-B046-9B92B8F44924Q57074357-960B8940-9AF3-4F94-912E-05A04131B65B
P2860
In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro activities of the bet ...... inetobacter baumannii strains.
@en
In vitro activities of the bet ...... inetobacter baumannii strains.
@nl
type
label
In vitro activities of the bet ...... inetobacter baumannii strains.
@en
In vitro activities of the bet ...... inetobacter baumannii strains.
@nl
prefLabel
In vitro activities of the bet ...... inetobacter baumannii strains.
@en
In vitro activities of the bet ...... inetobacter baumannii strains.
@nl
P2093
P2860
P1476
In vitro activities of the bet ...... inetobacter baumannii strains.
@en
P2093
Danuta Stefanik
Harald Seifert
Hilmar Wisplinghoff
P2860
P304
P356
10.1128/AAC.48.5.1586-1592.2004
P407
P577
2004-05-01T00:00:00Z